DE69326250D1 - Neuropeptide y antagoniste - Google Patents

Neuropeptide y antagoniste

Info

Publication number
DE69326250D1
DE69326250D1 DE69326250T DE69326250T DE69326250D1 DE 69326250 D1 DE69326250 D1 DE 69326250D1 DE 69326250 T DE69326250 T DE 69326250T DE 69326250 T DE69326250 T DE 69326250T DE 69326250 D1 DE69326250 D1 DE 69326250D1
Authority
DE
Germany
Prior art keywords
pct
neuropeptide
peptides
sec
antagoniste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69326250T
Other languages
German (de)
English (en)
Inventor
Alejandro Daniels
Dennis Heyer
Antonio Landavazo
Johann Leban
Andreas Spaltenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69326250D1 publication Critical patent/DE69326250D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69326250T 1992-06-20 1993-06-18 Neuropeptide y antagoniste Expired - Lifetime DE69326250D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929213215A GB9213215D0 (en) 1992-06-20 1992-06-20 Peptides
PCT/GB1993/001297 WO1994000486A1 (en) 1992-06-20 1993-06-18 Neuropeptide y antagonists

Publications (1)

Publication Number Publication Date
DE69326250D1 true DE69326250D1 (de) 1999-10-07

Family

ID=10717514

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69326250T Expired - Lifetime DE69326250D1 (de) 1992-06-20 1993-06-18 Neuropeptide y antagoniste

Country Status (12)

Country Link
US (1) US5670482A (enExample)
EP (1) EP0672055B1 (enExample)
JP (1) JPH07508273A (enExample)
AT (1) ATE184022T1 (enExample)
AU (1) AU4348893A (enExample)
CA (1) CA2138374A1 (enExample)
DE (1) DE69326250D1 (enExample)
GB (1) GB9213215D0 (enExample)
IL (1) IL106060A (enExample)
MX (1) MX9303694A (enExample)
TW (1) TW279166B (enExample)
WO (1) WO1994000486A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5696093A (en) * 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) * 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
DE69724941T2 (de) * 1996-03-21 2004-07-15 Banyu Pharmaceutical Co., Ltd. Aminopyridin-derivate
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
AU6309698A (en) * 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US6046167A (en) * 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
WO2000030674A1 (en) * 1998-11-26 2000-06-02 Ferring Bv Neuropeptide y y4 agents in the treatment of reproductive disorders
WO2001053477A1 (en) * 2000-01-20 2001-07-26 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of neuropeptide y activity
EP2002827A2 (en) 2001-12-05 2008-12-17 The Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
EP1620091B1 (en) 2003-05-05 2010-03-31 Probiodrug AG Inhibitors of glutaminyl cyclase
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005075436A2 (en) 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP1877076A4 (en) * 2005-04-15 2012-02-01 Regenertech Pty Ltd USE OF NEUROPEPTIDES Y (NPY) AND AGONIST OF ANTAGONISTS THEREOF FOR REGENERATING TISSUES
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2493879B1 (en) * 2009-10-28 2014-05-14 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602019A (en) * 1983-04-22 1986-07-22 Warner-Lambert Company Indeno[1,2-c]pyridazin-3-one derivatives useful as cardiotonic and antihypertensive agents
US5128332A (en) * 1984-10-23 1992-07-07 Perstorp Ab Method of treating cardiovascular diseases using inositoltrisphosphate
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US4891357A (en) * 1985-02-11 1990-01-02 University Of Florida Methods and compositions for stimulation of appetite
US4897445A (en) * 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
JPS646294A (en) * 1987-02-09 1989-01-10 Ajinomoto Kk Novel peptide derivative
US4839343A (en) * 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
US6255067B1 (en) * 1987-09-15 2001-07-03 The Johns Hopkins University cDNA encoding peptidyl-glycine alpha-amidating monooxygenase (PAM)
DE3811193A1 (de) * 1988-04-01 1989-10-19 Boehringer Ingelheim Kg Neue peptide, verfahren zu ihrer herstellung und diese peptide enthaltende pharmazeutische zusammensetzungen
DE3813592A1 (de) * 1988-04-22 1989-11-02 Hoechst Ag Monoklonale antikoerper gegen das neuropeptid y, verfahren zu ihrer herstellung sowie ihre verwendung
US5328899A (en) * 1988-07-15 1994-07-12 The Salk Institute For Biological Studies NPY peptide analogs
ZA896376B (en) * 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y agonists
ZA896374B (en) * 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y antagonists
SE9002278L (sv) * 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel

Also Published As

Publication number Publication date
WO1994000486A1 (en) 1994-01-06
CA2138374A1 (en) 1994-01-06
JPH07508273A (ja) 1995-09-14
IL106060A0 (en) 1993-10-20
MX9303694A (es) 1994-05-31
US5670482A (en) 1997-09-23
IL106060A (en) 1998-10-30
AU4348893A (en) 1994-01-24
EP0672055A1 (en) 1995-09-20
TW279166B (enExample) 1996-06-21
ATE184022T1 (de) 1999-09-15
GB9213215D0 (en) 1992-08-05
EP0672055B1 (en) 1999-09-01

Similar Documents

Publication Publication Date Title
MX9303694A (es) Peptidos.
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
BR9611175B1 (pt) compostos e composiÇÕes farmacÊuticas.
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
PL310171A1 (en) Novel imidazopyridines
DK0705100T3 (da) Terapeutiske substituerede guanidiner
DK0703788T3 (da) Stabiliseret phenylalaninammoniaklyase
SE9101838D0 (sv) Novel peptides and their use
IL117209A0 (en) 1-aryl-2-acylamino-ethane compounds and pharmaceutical compositions containing them
DE69334146D1 (de) Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung
DK0633763T3 (da) Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
NO971997D0 (no) Bruk av immunmodulerende midler
MY125854A (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
DE69307895D1 (de) Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin
ES2091039T3 (es) Nuevos bis-fenil-hexenos.
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
GR1002385B (el) Καθαρη μορφη στρεπτογραμινων, παρασκευη αυτης και φαρμακευτικες συνθεσεις που την περιεχουν.
SE9301831D0 (sv) Pharmaceutical compositions
ZA939199B (en) Methylbutoxy-propionitriles
NO950723D0 (no) Optisk aktivt hydrokinin-1-(3-aminofenyl)etansulfonat, dets fremstilling og anvendelse
RU93055684A (ru) Соединения, ингибирующие вич-протеазу, способ их получения, фармацевтическая композиция, промежуточный продукт
HU9602923D0 (en) Gonadotropins containing disuphidbridges which are not occuring in the nature

Legal Events

Date Code Title Description
8332 No legal effect for de